Profile data is unavailable for this security.
About the company
PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its lead program PAX-101 is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders fragile X syndrome (FXS), FXTAS, ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.
- Revenue in USD (TTM)0.00
- Net income in USD-18.15m
- Incorporated2018
- Employees6.00
- LocationPaxMedica Inc303 South Broadway, Suite 125TARRYTOWN 10591United StatesUSA
- Phone+1 (914) 987-2876
- Fax+1 (302) 636-5454
- Websitehttps://www.paxmedica.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aclarion Inc | 60.05k | -6.13m | 2.46m | 6.00 | -- | 0.8566 | -- | 40.98 | -7.41 | -7.41 | 0.0341 | 0.3502 | 0.0215 | -- | 3.50 | 10,008.33 | -219.26 | -- | -337.53 | -- | -29.49 | -- | -10,203.20 | -- | -- | -- | 0.211 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
| InMed Pharmaceuticals Inc | 5.63m | -6.08m | 2.47m | 13.00 | -- | 0.1686 | -- | 0.4383 | -1.23 | -1.23 | 0.9284 | 1.75 | 0.4006 | 2.71 | 29.77 | -- | -43.26 | -88.10 | -50.03 | -104.19 | 39.20 | -- | -108.01 | -1,066.11 | 5.80 | -- | 0.00 | -- | 279.60 | -- | 57.27 | -- | 29.56 | -- |
| Agile Therapeutics Inc | 21.50m | -7.79m | 2.48m | 19.00 | -- | -- | -- | 0.1152 | -3.65 | -3.65 | 6.98 | -1.51 | 1.63 | 2.90 | 5.42 | 1,131,316.00 | -59.25 | -94.24 | -- | -142.62 | 59.73 | -- | -36.26 | -513.50 | 0.3843 | -- | -- | -- | 80.02 | -- | 43.08 | -- | -- | -- |
| Mustang Bio Inc | 0.00 | -40.10m | 2.52m | 80.00 | -- | -- | -- | -- | -4.55 | -4.55 | 0.00 | -0.4757 | 0.00 | -- | -- | 0.00 | -90.93 | -70.02 | -138.05 | -79.98 | -- | -- | -- | -- | -- | -15.88 | -- | -- | -- | -- | 33.44 | -- | -60.75 | -- |
| Qrons Inc | 0.00 | -763.52k | 2.53m | 2.00 | -- | -- | -- | -- | -0.0562 | -0.0562 | 0.00 | -0.1078 | 0.00 | -- | -- | 0.00 | -18,782.78 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -19.02 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -17.46m | 2.56m | 3.00 | -- | -- | -- | -- | -3.58 | -3.58 | 0.00 | -0.4153 | 0.00 | -- | -- | 0.00 | -384.86 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
| PaxMedica Inc | 0.00 | -18.15m | 2.57m | 6.00 | -- | 2.07 | -- | -- | -11.19 | -11.19 | 0.00 | 0.1594 | 0.00 | -- | -- | 0.00 | -474.77 | -755.77 | -781.78 | -- | -- | -- | -- | -- | -- | -3,015.03 | 0.00 | -- | -- | -- | -23.56 | -- | -- | -- |
| cbdMD Inc | 21.58m | -25.65m | 2.57m | 52.00 | -- | 0.6561 | -- | 0.119 | -19.96 | -19.96 | 9.27 | 1.01 | 0.8949 | 2.09 | 21.27 | 415,039.60 | -89.78 | -38.59 | -118.26 | -41.50 | 62.70 | 63.80 | -100.33 | -87.98 | 0.6107 | -3.01 | 0.4668 | -- | -31.77 | 120.91 | 63.64 | -- | -4.95 | -- |
| DSwiss Inc | 1.68m | 144.71k | 2.59m | 11.00 | 17.86 | 11.01 | 13.22 | 1.54 | 0.0007 | 0.0007 | 0.0081 | 0.0011 | 4.43 | 189.17 | 35.95 | 152,321.80 | 38.27 | -8.69 | 79.40 | -45.47 | 32.65 | 25.55 | 8.64 | -2.47 | 2.04 | 66.93 | 0.1198 | -- | -20.50 | 46.20 | -688.36 | -- | -66.17 | -- |
| Panacea Life Sciences Holdings Inc | 2.76m | -7.67m | 2.62m | 40.00 | -- | -- | -- | 0.9473 | -0.4554 | -0.4554 | 0.164 | -0.5255 | 0.1537 | 1.62 | 10.13 | 69,098.25 | -42.65 | -69.04 | -- | -225.03 | -139.49 | -181.62 | -277.51 | -505.41 | 0.0285 | -2.12 | 4.79 | -- | 46.59 | -- | 12.33 | -- | -- | -- |
| Axim Biotechnologies Inc | 85.35k | -5.59m | 2.62m | 6.00 | -- | -- | -- | 30.73 | -0.0249 | -0.0249 | 0.0003 | -0.0268 | 0.0214 | -- | -- | 14,225.00 | -140.13 | -154.34 | -- | -390.73 | -- | -- | -6,548.75 | -36,362.71 | -- | -1.16 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
| Eloxx Pharmaceuticals Inc | 0.00 | -20.48m | 2.67m | 18.00 | -- | -- | -- | -- | -9.06 | -9.06 | 0.00 | -6.53 | 0.00 | -- | -- | 0.00 | -124.43 | -115.27 | -- | -155.33 | -- | -- | -- | -- | -- | -16.69 | -- | -- | -- | -- | 45.95 | -- | -22.56 | -- |
| Aridis Pharmaceuticals Inc | 22.36m | -1.14m | 2.79m | 37.00 | -- | -- | -- | 0.1246 | -0.1845 | -0.1845 | 0.7074 | -0.2648 | 2.40 | -- | 58.45 | 604,297.30 | -12.24 | -120.16 | -- | -678.29 | -- | -- | -5.11 | -1,559.63 | -- | -- | -- | -- | 101.37 | 29.16 | 34.43 | -- | -34.84 | -- |
| Virax Biolabs Group Ltd | 0.00 | -1.71m | 2.79m | 5.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.8568 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | 0.0223 | -112.29 | -- | -- | -100.00 | -- | -162.50 | -- | -- | -- |
| Novelstem International Corp | 15.00k | -4.22m | 2.82m | 15.00 | -- | -- | -- | 187.84 | -0.09 | -0.09 | 0.0003 | -0.0478 | 0.0065 | -- | 10.00 | -- | -172.16 | -- | -1,011.77 | -- | -- | -- | -26,418.53 | -- | -- | -8.40 | 2.34 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to PaxMedica Inc's reporting currency: US Dollar USD
1.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Souders Financial Advisors LLCas of 31 Mar 2024 | 40.00k | 0.54% |
| Virtu Americas LLCas of 31 Mar 2024 | 37.32k | 0.50% |
| G1 Execution Services LLCas of 31 Mar 2024 | 26.09k | 0.35% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 16.49k | 0.22% |
| Tower Research Capital LLCas of 31 Mar 2024 | 7.02k | 0.09% |
| The Vanguard Group, Inc.as of 30 Apr 2024 | 3.24k | 0.04% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.78k | 0.02% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 58.00 | 0.00% |
| American Portfolios Advisors, Inc.as of 31 Mar 2024 | 2.00 | 0.00% |
| Clearstead Advisors, LLCas of 31 Mar 2024 | 1.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
